<DOC>
	<DOC>NCT02554136</DOC>
	<brief_summary>The investigators investigate the potential pharmacokinetic drug-drug interaction between HGP0918 and HGP0816 in healthy adult subjects who receive HGP0918 alone, HGP0816 alone, and both together in a 3 period repeatedly</brief_summary>
	<brief_title>Evaluating a Pharmacokinetic Drug Interaction Between HGP0918 and HGP0816</brief_title>
	<detailed_description />
	<criteria>Subjects who have ability to comprehend the objectives, contents of study and property of study drug before participating in trial and have willingness to sign of informed consent in writing Healthy male volunteers, aged 19 to 55 years. The result of Body Mass Index(BMI) is not less than 18.5 kg/m2 , no more than 27.0 kg/m2 Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in digestive system, neuropsychiatric system, endocrine system, liver, cardiovascular system Someone has a declined liver function and Liver enzyme (AST, ALT or total bilirubin) level exceeds more than one and a half times normal upper range Somenone has a declined kidney function and his eGFR &lt; 60mL/min/1.73m2</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>